UK Approval of Isodiol to Boost CBD Distribution

Isodiol International Inc., a leading bioactive CBD innovator, announced that its wholly-owned subsidiary BSPGL has received government approval from the United Kingdom (UK). The approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of UK is in accordance with The Human Medicines Regulations 2012. It allows the company to manufacture the active ingredient cannabidiol (CBD) in the country under certificate UK API 48727.

MHRA is a recognized regulatory authority of UK’s Department of Health. The agency controls the approval of medicines and medical devices. It plays a significant role in supporting breakthrough research and development while securing and enhancing public health. The agency is also an important part of the European system of approval.

The approval signifies the commitment and consistency of Isodiol and BSPGL in developing pure, natural, and pharmaceutical-grade CBD. The company uses its patent-protected manufacturing process to produce bioactive CBD. This approval will help the company focus on innovating CBD drugs to treat a wide array of diseases. The company now aims to speed up its pharmaceutical and drug development to meet the rising demand for effective treatments.

In addition to this, the approval enables the company to export pure and bioactive CBD around the globe, which will help with CBD distribution. This approval from the UK government has positioned Isodiol as a reliable and secure supplier of CBD. The company will now be able to cater to the demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials.

The company is all set to finish its new state-of-the-art manufacturing facility in the first quarter of 2019. This facility will increase its output capabilities to around 20,000 kilos annually.

Isodiol acquired 100% BSPGL (BioSynthesis Pharma Group Laboratories) in April 2018 to produce and extract 99.5% pure and bioactive CBD molecules. BSPGL is known for producing and extracting the purest and pharmaceutical grade CBD. It uses its proprietary industrial scale extraction methodologies to refine the active ingredient with no tetrahydrocannabinol (THC).


Read more: ‘CBD: The Biotech Boom Investors Haven’t Woken Up To Yet’

Leave a Reply

Your email address will not be published.